In a posttransplant setting, patients with a reactive QuantiFERON-CMV test remain free from CMV disease significantly more often, and for longer, than patients with a nonreactive QuantiFERON-CMV test after the cessation of antiviral prophylaxis. This indicates QuantiFERON-CMV may predict development of late-onset CMV in transplant recipients (2).
In a theoretical model of QuantiFERON-CMV responses in a posttransplant setting, during and/or following prophylaxis and immune suppression, robust immune responses are associated with a decreased risk of CMV disease occurrence. A robust immune response in the CMV Antigen tube may be indicative of immunity to CMV.
